Additional genetic alterations, including amplification of the EGFR gene and the loss of heterozygosity on chromosome 10q (often involving the PTEN tumor suppressor gene), further contribute to the molecular profile of the tumor and may inform targeted therapeutic options in the context of clinical trials [10]. This evidence concerns the gene EGFR and neoplasm.